David Wu, Chief Operating Officer (COO) and co-founder.

Mr. Wu is a seasoned scientist with proven leadership in developing PEGylated anti-cancer drug for IND filings and phase I/II clinical trials. During his 20-year tenure in Enzon Pharmaceuticals Inc, he witnessed the development of PEGylation technology and contributed significantly to move four PEGylated drug candidates into IND filings and clinical trials. Mr. Wu is an expert in PEGylation technology and author or co-author more than 40 issued patents, patent applications and scientific publications. He also worked for Jonson & Jonson and other companies with critical role. He received his M.S. degree in Chemistry from Catholic University of America and MBA in Finance from Montclair State University in US.